Atenolol

Introduction Overview

Generic Name

atenolol

Brand Name

Tenormin

Dosage Form

oral tablet (25 mg; 50 mg; 100 mg)

Drug Class

Cardioselective beta blockers

Pharmacokinetics

Absorption

Atenolol is well absorbed after oral administration, with bioavailability ranging from 40% to 50%. Absorption occurs primarily in the gastrointestinal tract, with peak plasma concentrations typically reached within 2 to 4 hours post-dose. Food has minimal effect on the extent of absorption but may slightly delay the time to peak concentration. Atenolol's absorption is reliable and consistent, making oral dosing effective for clinical use.

Distribution

Following absorption, atenolol exhibits a relatively low volume of distribution (approximately 0.7 L/kg), indicating limited tissue binding. It is minimally bound (6-16%) to plasma proteins, predominantly albumin. Due to its hydrophilic nature, atenolol does not readily cross lipid membranes, including the blood-brain barrier, contributing to fewer central nervous system side effects compared to lipophilic beta blockers. The drug distributes mainly in the extracellular fluid compartment.

Metabolism

Unlike many beta blockers, atenolol undergoes little to no hepatic metabolism. It remains predominantly in its unchanged active form in the systemic circulation. This lack of hepatic biotransformation reduces the risk of drug interactions related to hepatic enzyme induction or inhibition, and makes atenolol a preferred agent in patients with hepatic impairment. Minor metabolism may occur but is clinically insignificant.

Elimination

Atenolol is primarily eliminated unchanged by renal excretion via glomerular filtration and active tubular secretion. Approximately 85% or more of a dose is excreted unchanged in urine over 48 to 96 hours. Its elimination half-life ranges from 6 to 7 hours in individuals with normal renal function, but this duration is prolonged substantially in patients with renal impairment, necessitating dose adjustments. Because of this renal clearance, monitoring renal function is important in patients on atenolol therapy.

Dosage Forms

Adults

For hypertension, the usual initial oral dose of atenolol is 50 mg once daily, with maintenance doses ranging from 50 to 100 mg daily. In angina pectoris prophylaxis, treatment begins at 50 mg once daily and may be increased to 100 mg or up to 200 mg daily depending on clinical response. For management post-myocardial infarction, dosing typically involves 50 mg twice daily or 100 mg once daily, continued for 1 to 3 years if tolerated and not contraindicated.

Adolescents

Atenolol is not approved for use in patients younger than 18 years old; hence dosing recommendations are not established for the pediatric or adolescent population.

Special Populations

In geriatric patients, the initial dose is often reduced to 25 mg once daily due to potential decreased renal clearance and increased sensitivity to beta blockers. Renal impairment significantly extends atenolol's elimination half-life, warranting dose reduction and careful monitoring. Hepatic impairment has minimal influence on dosing due to minimal hepatic metabolism. Atenolol should be used with caution during pregnancy owing to potential fetal risks and breastfeeding due to excretion into breast milk.

Mechanism Of Action

Atenolol is a selective beta-1 adrenergic receptor antagonist commonly referred to as a cardioselective beta blocker. It binds competitively to beta-1 adrenergic receptors located primarily in cardiac tissue, effectively blocking the action of endogenous catecholamines such as norepinephrine and epinephrine. This blockade results in a decreased heart rate (negative chronotropic effect), reduced myocardial contractility (negative inotropic effect), and lower cardiac output, thereby reducing myocardial oxygen demand.

At the cellular level, atenolol inhibits the Gs protein-coupled receptor-mediated activation of adenylate cyclase, leading to decreased cyclic AMP production within cardiac myocytes. This lowers intracellular calcium concentrations responsible for muscle contraction and pacemaker activity in the sinoatrial node, contributing to the slowing of heart rate and conduction velocity.

Clinically, the cardioselectivity of atenolol at beta-1 receptors limits its effects on beta-2 receptors found in bronchial and vascular smooth muscles, reducing the risk of bronchoconstriction. However, selectivity is dose-dependent and may diminish at higher doses. Atenolol’s ability to reduce blood pressure is also partly due to decreased renin release from juxtaglomerular cells in the kidney, an effect mediated via beta-1 blockade, contributing to its antihypertensive action.

Compared with nonselective beta blockers such as propranolol, atenolol offers advantages in patients with respiratory conditions like asthma. Extensive clinical studies have supported atenolol’s efficacy in managing hypertension, angina pectoris, and reducing mortality post-myocardial infarction through its beta-1 antagonist activity.

Pharmacological Actions

Selective blockade of beta-1 adrenergic receptors in cardiac tissue
Reduction of heart rate (negative chronotropic effect)
Decrease in myocardial contractility (negative inotropic effect)
Lowering cardiac output to reduce blood pressure
Suppression of renin release from the kidneys
Reduction of myocardial oxygen demand
Limited impact on beta-2 receptors at therapeutic doses, minimizing bronchoconstriction
Management of arrhythmias through slowing atrioventricular conduction
Improvement of exercise tolerance in angina pectoris
Attenuation of reflex tachycardia associated with vasodilators
Negative effect on cardiac conduction which can prevent excessive adrenergic stimulation
Reduction of sympathetic nervous system overactivity post-myocardial infarction
Minimal central nervous system penetration reducing CNS-related side effects
Prolongation of AV nodal refractory period potentially beneficial in supraventricular tachycardias
Antihypertensive effect through combined cardiac and renal (renin suppression) mechanisms

Therapeutic Clinical Uses

Treatment of hypertension, alone or in combination with other antihypertensive agents
Prophylaxis and long-term management of angina pectoris
Reduction of morbidity and mortality following acute myocardial infarction
Management of hemodynamically stable patients post-myocardial infarction
Control of certain types of cardiac arrhythmias
Use in patients with coronary artery disease to improve symptoms and prognosis
Treatment of essential hypertension with consideration of patient-specific factors
Off-label uses may include migraine prophylaxis and thyrotoxicosis management
Adjunctive therapy to reduce cardiovascular workload in certain conditions
Prevention of reflex tachycardia when combined with vasodilators
Reduction in progression of left ventricular hypertrophy in hypertensive patients
Control of heart rate in supraventricular tachycardias
Management of anxiety-related tachycardia (less common)
Part of comprehensive cardiovascular risk reduction strategies

Side Or Adverse Effects

Bradycardia (slow heart rate)
Fatigue and tiredness
Dizziness and lightheadedness
Cold extremities (hands and feet) due to peripheral vasoconstriction
Depressed mood and potential mood changes
Hypotension (low blood pressure)
Worsening of heart failure in susceptible individuals
Shortness of breath or bronchospasm in sensitive patients
Sleep disturbances including insomnia or vivid dreams
Gastrointestinal disturbances such as nausea or diarrhea
Sexual dysfunction including decreased libido
Exacerbation of Raynaud's phenomenon
Potential masking of hypoglycemia symptoms in diabetics
Rare allergic reactions including rash or hypersensitivity
Potential for atrioventricular block or cardiac conduction abnormalities

Precautions

Use with caution in patients with congestive heart failure
Monitor closely in patients with coronary artery disease
Avoid abrupt cessation to prevent rebound hypertension or angina exacerbation
Use cautiously in patients with bronchospastic airway diseases despite cardioselectivity
Adjust doses in renal impairment to avoid toxicity
Monitor blood glucose carefully in diabetic patients as beta blockers may mask hypoglycemia signs
Consider potential interactions with other cardiac medications
Avoid in patients with sick sinus syndrome or second- or third-degree AV block without a pacemaker
Use cautiously during pregnancy and breastfeeding due to potential fetal/neonatal adverse effects
Assess risk-benefit in elderly patients due to increased sensitivity
Avoid in patients with severe peripheral arterial disease
Inform patients about possible CNS effects such as fatigue or dizziness
Regularly monitor heart rate and blood pressure during therapy
Evaluate renal and hepatic function periodically
Avoid concomitant use with other beta blockers unless specifically indicated

Warnings

Contraindicated in patients with second- or third-degree AV block
Contraindicated in patients with sinus bradycardia and cardiogenic shock
Not recommended in acute heart failure settings without specialist supervision
Do not stop atenolol abruptly; taper dose gradually to reduce risk of exacerbation of angina or myocardial infarction
May impair alertness and reaction times; caution patients when driving or operating machinery
Potential to mask symptoms of hyperthyroidism and hypoglycemia
Use with caution during anesthesia as beta blockade may interfere with some anesthetic agents
Monitor for signs of worsening heart failure during treatment
May interact with other cardiac drugs leading to additive bradycardia or hypotension
May cause fetal harm if administered during pregnancy
Avoid alcohol consumption which may worsen sedation and dizziness
Regular monitoring recommended in patients undergoing surgery who are on atenolol
Be alert for signs of anaphylaxis; beta blockers may worsen allergic reactions
Ensure patient compliance to reduce risks associated with missed doses
Use cautiously in patients with peripheral vascular disease due to potential worsening of symptoms

Contraindications

Second- or third-degree atrioventricular (AV) block
Sinus bradycardia
Cardiogenic shock
Overt cardiac failure without adequate therapy
Known hypersensitivity to atenolol or other beta blockers
Severe peripheral arterial disease with risk of limb ischemia
Sick sinus syndrome (unless pacemaker is present)
Severe asthma or bronchospastic conditions where beta-1 selectivity is insufficient to prevent bronchoconstriction
Untreated phaeochromocytoma without alpha blockade
Severe hypotension
Acute myocardial infarction complicated by heart failure or low output state without specialist supervision
Concurrent use with other beta blockers without clear indication
Known allergy to any component of the formulation

Drug Interactions

Additive bradycardia and atrioventricular block when combined with digoxin or other cardiac conduction blocking agents
Reduced antihypertensive efficacy or increased risk of adverse effects with nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin
Enhanced beta-blocking effects when used with other beta blockers (bisoprolol, carvedilol, metoprolol, propranolol, sotalol, timolol)
Potential for hypotension and bradycardia when combined with calcium channel blockers like verapamil and diltiazem
Increased risk of severe bradycardia or heart block when used with amiodarone
Altered pharmacodynamics with clonidine; abrupt clonidine withdrawal with atenolol may exacerbate hypertension
Caution with antiarrhythmics like disopyramide due to additive negative inotropic and chronotropic effects
Beta-blocker effects may be potentiated by reserpine
Possible interference with response to hypoglycemic agents; atenolol may mask symptoms of hypoglycemia
Interference with catecholamine pressor agents leading to unpredictable blood pressure effects
Potential interaction with nicardipine and nifedipine influencing heart rate and blood pressure
Increased plasma levels and effects when combined with cimetidine have been reported
Concurrent use with other CNS depressants may enhance sedation
Reduced efficacy of beta agonists used for asthma treatment due to receptor blockade
Interactions with herbal supplements that affect heart rate or blood pressure, such as St. John's Wort, are possible

Preparations Of The Drug

Oral tablets available in 25 mg strength
Oral tablets available in 50 mg strength
Oral tablets available in 100 mg strength
Commercially marketed under the brand name Tenormin
Available as generic formulations of atenolol tablets
Tablets formulated for once-daily oral administration
Packaged in various counts to accommodate long-term therapy
Prescribed as monotherapy or in combination regimens for hypertension or angina
No intravenous formulation commonly used; atenolol injection available but less common than oral forms
Tablets are typically film-coated for ease of swallowing
Supplied in light-resistant containers to protect drug stability
Formulations designed for consistent bioavailability across batches
No extended-release or sustained-release formulations widely available
Usually administered orally without regard to meals, though consistent timing is recommended